Using ravulizumab to treat severe preeclampsia in pregnant women
Official title: Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Run by Mayo Clinic · NCT06333652 · Data updated 2026-11-12
This study is testing if the medication ravulizumab can help pregnant women with severe preeclampsia and HELLP syndrome feel better and stay safe.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 14 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | Ravulizumab |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | April 1, 2027 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT06333652 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant women under 34 weeks of gestation diagnosed with severe preeclampsia or HELLP features.
✕Probably not a fit
Patients with conditions such as disseminated intravascular coagulopathy, non-viable fetuses, or those requiring immediate delivery will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is investigating the efficacy of ravulizumab, a medication, in treating severe preeclampsia and HELLP syndrome in pregnant women who are less than 34 weeks gestation. The study aims to assess the safety and effectiveness of this intervention in managing these serious pregnancy complications. Participants will be closely monitored for improvements in their condition and any potential side effects from the treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve outcomes for pregnant women suffering from severe preeclampsia and HELLP syndrome.
How similar studies have gone: While this approach is novel in the context of severe preeclampsia, similar studies using targeted therapies for pregnancy-related complications have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals with \< 34 0/7 weeks of gestation. * Individuals with severe preeclampsia or HELLP features. Exclusion Criteria: * Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC). * Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Where it's running
-
Mayo Clinic Minnesota
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Maria Lourdes Gonzalez Suarez, MD, PhD — Mayo Clinic
- Study coordinator: Gonzalez Suarez
- Phone: 507-284-2511
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy
This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.
-
Higher vs lower daily aspirin in high-risk pregnant people
This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Role of Progesterone Membrane Receptors in Preeclampsia
This study looks at whether the levels of progesterone membrane receptors in the placenta differ between women with preeclampsia and healthy pregnant women to understand the condition better.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.